At a glance
| Target | GLP-1 receptor |
|---|---|
| Standalone name | Adlyxin |
| Combination | Soliqua with insulin glargine |
| Route | Subcutaneous injection |
| Outcome trial | ELIXA |
Overview
The standalone medicine was approved as Adlyxin, while Soliqua 100/33 combines lixisenatide with basal insulin glargine. These products must be distinguished because the combination adds insulin’s hypoglycemia and medication-error risks. Current DailyMed information confirms the combination’s adult type 2 diabetes indication. Lixisenatide is not an approved obesity treatment or a replacement for insulin in type 1 diabetes. Its place in diabetes care depends on the actual product, renal function, gastrointestinal tolerance and the broader regimen rather than the assumption that all GLP-1 agents have identical outcome evidence.
How it works
Lixisenatide activates GLP-1 receptors to support glucose-dependent insulin secretion, suppress inappropriate glucagon release and delay gastric emptying. The gastric effect contributes to control of post-meal glucose but can also change absorption of oral medicines. In a fixed insulin-glargine combination, the two components address different parts of glycemic control; the combination is not equivalent to lixisenatide alone.
Standalone and combination roles
Adlyxin’s label covers adult type 2 diabetes. Soliqua is also an adult diabetes product but contains both insulin and lixisenatide. The combination is not recommended for diabetic ketoacidosis and has not been studied with prandial insulin.
Cardiovascular trial interpretation
ELIXA studied patients with type 2 diabetes after a recent acute coronary event. Lixisenatide was noninferior to placebo for the cardiovascular safety endpoint, but did not show superiority. This should not be rewritten as the cardiovascular benefit demonstrated by some other GLP-1 medicines.
Supporting sources [3]
Adverse effects and kidney considerations
Nausea, vomiting, diarrhea and other gastrointestinal symptoms are common. Pancreatitis, serious allergy, gallbladder disease and dehydration-related kidney injury are label concerns. Severe gastroparesis and end-stage renal disease require particular attention to product restrictions.
Gastric emptying and oral medicines
Delayed gastric emptying can alter the timing of oral-drug exposure. The label contains specific considerations for medicines whose prompt absorption matters, including some contraceptives. Anesthesia teams also need to know about GLP-1 treatment because of aspiration concerns.
What changes when insulin is included?
The fixed combination introduces basal-insulin activity and its associated hypoglycemia risk. Device settings, product limits and switching instructions belong to that combination’s label; they cannot be inferred from a standalone lixisenatide description.
Supporting sources [2]
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Exendin-based GLP-1 receptor agonist peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- FDA: Adlyxin prescribing information ↗Regulatory source · Checked 2026-10-27
- DailyMed: Soliqua 100/33 current prescribing information ↗Regulatory source · Checked 2026-10-27
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. ↗Original research · Checked 2026-10-27